Fast, ready-to-use migraine pain relief1-3
Tosymra® delivers migraine pain relief in as little as 10 minutes with just one spray for some patients (13% vs. 5% for placebo).*1-3
Efficacy of Tosymra® is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.1
*Time to onset and degree of pain relief varies by patient.
Tosymra® uses the science of Intravail®
Tosymra® is the first and only triptan nasal spray to use the novel ingredient Intravail® to enhance drug absorption across the nasal mucosa.4
Tosymra® for as little as $0†
The Access Pathways® Program is a best-in-class savings and support program. Access Pathways®, in partnership with Blink Pharmacy Plus, offers:
Eligible commercially insured patients may pay as little as $0† per prescription, per month with free home delivery through Blink Pharmacy Plus
Dedicated customer support to guide you and your patients through the process
†Restrictions and quantity limits apply. Click to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.
Want more information?
Sign up today to learn more about Tosymra®.
- Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
- Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
- Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.
- Maggio ET. Intravail®: highly effective intranasal delivery of peptide and protein drugs. Expert Opinion Drug Delivery. 2006;3(4):529-539.